CELGENE CORP (CELG) Stock Price & Overview
NASDAQ:CELG
The current stock price of CELG is 108.24 null. Today CELG is up by 0.1%. In the past month the price increased by 3.1%. In the past year, price increased by 62.4%.
CELG Key Statistics
- Market Cap
- 77.036B
- P/E
- 11.00
- Fwd P/E
- 9.14
- EPS (TTM)
- 9.84
- Dividend Yield
- N/A
CELG Stock Performance
CELG Stock Chart
CELG Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CELG. When comparing the yearly performance of all stocks, CELG is one of the better performing stocks in the market, outperforming 94.89% of all stocks.
CELG Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to CELG. CELG has an excellent profitability rating, but there are some minor concerns on its financial health.
CELG Earnings
CELG Forecast & Estimates
CELG Financial Highlights
Over the last trailing twelve months CELG reported a non-GAAP Earnings per Share(EPS) of 9.84. The EPS increased by 33.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 34.62% | ||
| ROA | 14.22% | ||
| ROE | 48.65% | ||
| Debt/Equity | 1.51 |
CELG Ownership
About CELG
Company Profile
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, OTEZLA, ISTODAX and IDHIFA. The drug candidates in their pipeline are at various stages of preclinical and clinical development. These candidates include their IMiDs compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to their leading oral anti-inflammatory agents and cellular therapies. They believe their commercial stage products and the depth of their product pipeline, provide the catalysts for future growth.
Company Info
CELGENE CORP
86 MORRIS AVENUE
SUMMIT NJ 07901
CEO: Mark J. Alles
Phone: 908-673-9000
CELGENE CORP / CELG FAQ
What does CELG do?
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, OTEZLA, ISTODAX and IDHIFA. The drug candidates in their pipeline are at various stages of preclinical and clinical development. These candidates include their IMiDs compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to their leading oral anti-inflammatory agents and cellular therapies. They believe their commercial stage products and the depth of their product pipeline, provide the catalysts for future growth.
What is the stock price of CELGENE CORP today?
The current stock price of CELG is 108.24 null. The price increased by 0.1% in the last trading session.
Does CELG stock pay dividends?
CELG does not pay a dividend.
How is the ChartMill rating for CELGENE CORP?
CELG has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Would investing in CELGENE CORP be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CELG.
What is CELGENE CORP worth?
CELGENE CORP (CELG) has a market capitalization of 77.04B null. This makes CELG a Large Cap stock.